Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) sees J.P. Morgan raise price target to $49 from $48, maintaining a Hold rating. FDA approval of Dawnzera for hereditary angioedema noted as positive, with a long dosing interval as a key advantage despite pricing concerns. Stock falls 3.28% post-approval.

Analyst cautious on Ionis Pharmaceuticals (IONS) due to drug pricing, uncertain market reaction despite FDA approval of Dawnzera. Company develops medicines for serious diseases, focusing on neurologic and cardiovascular conditions. Potential investment, but AI stocks may offer greater upside potential and less downside risk.

Read more at Yahoo Finance: J.P. Morgan Raises the PT on Ionis Pharmaceuticals (IONS), Keeps a Hold Rating